Hims & Hers Health, Inc. CFO Okupe Oluyemi sold 7,163 shares on July 17, 2026 at $31.99 per share, for a total value of about $229.17K. The sale was reported as being made under a pre-scheduled Rule 10b5-1 trading plan, meaning the timing and amount were set in advance and the trade can occur automatically regardless of day-to-day news. This matters because the chief financial officer is a top executive with visibility into the company’s financial performance, cash position, and guidance-related processes. Investors often watch CFO trades closely for signs of confidence or caution, but 10b5-1 plan transactions generally carry less informational weight than discretionary, open-market trades because they are designed to reduce the appearance of trading on nonpublic information. Over the last 30 days, the only disclosed insider activity at HIMS was this single sale by Okupe. With no additional recent buys or multiple insiders trading in the same direction, the filing reads more like a routine, planned liquidity or diversification event than a broader shift in insider behavior.